| Literature DB >> 36117592 |
Ruo-Yang Chen1, Sheng Zhang2, Shao-Yong Zhuang1, Da-Wei Li1, Ming Zhang1, Cheng Zhu3, Yue-Tian Yu4, Xiao-Dong Yuan1.
Abstract
Objective: To investigate the risk factors of infectious diseases in adult kidney transplantation recipients and to establish a simple and novel nomogram to guide the prophylactic antimicrobial therapy.Entities:
Keywords: infectious disease; kidney transplantation; nomogram; prediction model; solid organ transplantation
Mesh:
Substances:
Year: 2022 PMID: 36117592 PMCID: PMC9471136 DOI: 10.3389/fpubh.2022.944137
Source DB: PubMed Journal: Front Public Health ISSN: 2296-2565
Figure 1Flow chart of the study.
Demographics and clinical characteristics of patiovents with or without infectious disease.
|
|
|
| ||
|---|---|---|---|---|
|
|
|
| ||
| Gender, | 1.000 | |||
| Female | 344 (39.9) | 182 (39.9) | 162 (39.8) | |
| Male | 519 (60.1) | 274 (60.1) | 245 (60.2) | |
| Age, median (IQR), years | 43 (35, 52) | 42 (35, 52) | 43 (35, 52) | 0.736 |
| Blood type, | 0.468 | |||
| O type | 301 (34.9) | 155 (34.0) | 146 (35.9) | |
| A type | 255 (29.5) | 128 (28.1) | 127 (31.2) | |
| B type | 208 (24.1) | 116 (25.4) | 92 (22.6) | |
| AB type | 99 (11.5) | 57 (12.5) | 42 (10.3) | |
| Dialysis before operation, | 0.315 | |||
| No | 45 (5.2) | 20 (4.4) | 25 (6.1) | |
| Yes | 818 (94.8) | 436 (95.6) | 382 (93.9) | |
| Diabetes, | 0.457 | |||
| No | 846 (98.1) | 445 (97.6) | 401 (98.5) | |
| Yes | 17 (1.9) | 11 (2.4) | 6 (1.5) | |
| Hypertension, | 0.590 | |||
| No | 720 (83.4) | 377 (82.7) | 343 (84.3) | |
| Yes | 143 (16.6) | 79 (17.3) | 64 (15.7) | |
| Delayed graft function, | <0.001 | |||
| No | 664 (76.9) | 377 (82.7) | 287 (70.5) | |
| Yes | 199 (23.1) | 79 (17.3) | 120 (29.5) | |
| Glucocorticoid, | 0.384 | |||
| Methylprednisolone | 773 (89.6) | 403 (88.4%) | 370 (90.9%) | |
| Metacortandracin | 78 (9.0) | 47 (10.3%) | 31 (7.62%) | |
| Prednisolone | 12 (1.4) | 6 (1.32%) | 6 (1.47%) | |
| Tacrolimus, | 0.329 | |||
| No | 124 (14.4) | 60 (13.2) | 64 (15.7) | |
| Yes | 739 (85.6) | 396 (86.88) | 343 (84.3) | |
| Immunity induction, | 0.577 | |||
| Thymoglobulin | 820 (95.0) | 431 (94.5) | 389 (95.6) | |
| Basiliximab | 43 (5.0) | 25 (5.5) | 18 (4.4) | |
| WBC, median (IQR), 109/L | 7.1 (5.6, 9.3) | 7.8 (6.1,10.3) | 6.7 (5.0, 8.2) | <0.001 |
| Neutrophil percentage, median (IQR), % | 80.3 | 82.2 | 78.0 | <0.001 |
| Platelet, median (IQR), 109/L | 215 (168, 264) | 216 (173, 268) | 215 (164, 254) | 0.058 |
| Globulin, median (IQR), g/L | 22.7 | 23.5 | 22.5 | <0.001 |
| Albumin infusion: | <0.001 | |||
| No | 261 (30.2) | 201 (44.1) | 60 (14.7) | |
| Yes | 602 (69.8) | 255 (55.9) | 347 (85.3) | |
| RBC infusion: | <0.001 | |||
| No | 361 (41.8) | 250 (54.8) | 111 (27.3) | |
| Yes | 502 (58.2) | 206 (45.2) | 296 (72.7) | |
| Prealbumin, median (IQR), mg/L | 291 (71.1) | 283 (66.2) | 299 (75.2) | 0.001 |
| Alanine transaminase, median (IQR), U/L | 16.0 | 17.0 | 16.0 | 0.005 |
| Aspartate aminotransferase, median (IQR), U/L | 15.0 | 15.0 | 15.0 | 0.307 |
| Direct bilirubin, median (IQR), umol/L | 2.6 (2.0, 3.5) | 2.6 (2.1, 3.8) | 2.6 (2.0, 3.1) | 0.004 |
| Total bilirubin, median (IQR), umol/L | 7.7 (6.3, 10.0) | 7.7 (6.4, 10.6) | 7.7 (6.2, 9.3) | 0.090 |
| Urea, median (IQR), mmol/L | 9.6 (7.6, 13.5) | 9.5 (7.2, 12.7) | 9.6 (7.9, 14.2) | 0.003 |
| Creatinine, median (IQR), umol/L | 117 (93, 162) | 107 (82, 136) | 128 (108, 217) | <0.001 |
| Uric acid, median (IQR), umol/L | 304 (252, 370) | 282 (230, 344) | 321 (288, 394) | <0.001 |
| Triglyceride, median (IQR), mmol/L | 1.8 (1.6, 2.1) | 1.8 (1.5, 2.2) | 1.8 (1.7, 2.1) | 0.474 |
| Cholesterol, median (IQR), mmol/L | 4.5 (4.1, 4.9) | 4.5 (3.8, 4.6) | 4.5 (4.5, 5.2) | <0.001 |
| Blood glucose, median (IQR), mmol/L | 4.9 (4.5, 5.4) | 4.9 (4.3, 5.2) | 4.9 (4.9, 5.6) | <0.001 |
Demographics and clinical characteristics of patients in testing and training groups.
|
|
|
| ||
|---|---|---|---|---|
|
|
|
| ||
| Gender, | 0.461 | |||
| Female | 344 (39.9) | 166 (38.5) | 178 (41.2) | |
| Male | 519 (60.1) | 265 (61.5) | 254 (58.8) | |
| Age, median (IQR), years | 43 (35, 52) | 42 (35, 52) | 43 (35, 52) | 0.615 |
| Infection, | 0.261 | |||
| No | 456 (52.8) | 219 (50.8) | 237 (54.9) | |
| Yes | 407 (47.2) | 212 (49.2) | 195 (45.1) | |
| Infection types, | 0.337 | |||
| Non-infection | 456 (52.8) | 219 (50.8) | 237 (54.9) | |
| Bacterial infection | 73 (8.5) | 34 (7.9) | 39 (9.0) | |
| Fungal infection | 29 (3.4) | 13 (3.0) | 16 (3.7) | |
| Virus infection | 305 (35.3) | 165 (38.3) | 140 (32.4) | |
| Blood type, | 0.126 | |||
| O type | 301 (34.9) | 151 (35) | 150 (34.7) | |
| A type | 255 (29.5) | 136 (31.6) | 119 (27.5) | |
| B type | 208 (24.1) | 90 (20.9) | 118 (27.3) | |
| AB type | 99 (11.5) | 54 (12.5) | 45 (10.4) | |
| Dialysis before operation, | 0.766 | |||
| No | 45 (5.2) | 21 (4.9) | 24 (5.6) | |
| Yes | 818 (94.8) | 410 (95.1) | 408 (94.4) | |
| Diabetes, | 0.621 | |||
| No | 846 (98.0) | 421 (97.7) | 425 (98.4) | |
| Yes | 17 (2.0) | 10 (2.3) | 7 (1.6) | |
| Hypertension, | 0.572 | |||
| No | 720 (83.4) | 356 (82.6) | 364 (84.3) | |
| Yes | 143 (16.6) | 75 (17.4) | 68 (15.7) | |
| Outcomes, | 0.551 | |||
| Survival | 852 (98.7) | 427 (99.1) | 425 (98.4) | |
| Non-survival | 11 (1.3) | 4 (0.9) | 7 (1.6) | |
| Delayed graft function, | 0.323 | |||
| No | 664 (76.9) | 325 (75.4) | 339 (78.5) | |
| Yes | 199 (23.1) | 106 (24.6) | 93 (21.5) | |
| Glucocorticoid, | 0.485 | |||
| Methylprednisolone | 773 (89.6) | 383 (88.9) | 390 (90.3) | |
| Metacortandracin | 78 (9) | 40 (9.3) | 38 (8.8) | |
| Prednisolone | 12 (1.4) | 8 (1.9) | 4 (0.9) | |
| Anti-proliferation, | 0.281 | |||
| Mycophenolate mofetil | 740 (85.7) | 373 (86.5) | 367 (85.0) | |
| Mycophenol sodium | 123 (14.3) | 58 (13.5) | 65 (15.0) | |
| Tacrolimus, | 0.488 | |||
| No | 124 (14.4) | 66 (15.3) | 58 (13.4) | |
| Yes | 739 (85.6) | 365 (84.7) | 374 (86.6) | |
| Immunity induction, | 0.748 | |||
| Thymoglobulin | 820 (95) | 408 (94.7) | 412 (95.4) | |
| Basiliximab | 43 (5) | 23 (5.3) | 20 (4.6) | |
| WBC, median (IQR), 109/L | 7.1 (5.6, 9.3) | 7.1 (5.4, 9.4) | 7.1 (5.6, 9.2) | 0.489 |
| RBC, median (IQR), 1012/L | 3.1 (2.6, 3.7) | 3.1 (2.6, 3.7) | 3.1 (2.6, 3.6) | 0.263 |
| Neutrophil percentage, median (IQR), % | 80.3 | 80.3 | 80.3 | 0.680 |
| Lymphocyte percentage, median (IQR), % | 11.1 | 11.1 | 11.1 | 0.182 |
| Hemoglobin, median (IQR), g/L | 92 (80, 108) | 92 (80, 109) | 92 (80, 105.2) | 0.363 |
| Platelet, median (IQR), 109/L | 215 | 215 | 215 | 0.485 |
| Globulin, median (IQR), g/L | 22.7 | 22.7 | 22.7 | 0.926 |
| Albumin, median (IQR), g/L | 37.3 | 37.3 | 37.3 | 0.263 |
| Prealbumin, median (IQR), mg/L | 286 | 286 | 286 | 0.704 |
| Alanine transaminase, median (IQR), U/L | 16 (11, 25.5) | 16 (12, 26) | 16 (11, 25) | 0.602 |
| Aspartate aminotransferase, median (IQR), U/L | 15 (12, 19) | 15 (12, 19) | 15 (12, 19) | 0.846 |
| Direct bilirubin, median (IQR), umol/L | 2.6 (2, 3.5) | 2.6 (2, 3.5) | 2.6 (2.1, 3.5) | 0.173 |
| Total bilirubin, median (IQR), umol/L | 7.7 (6.3, 10) | 7.7 (6, 10) | 7.7 (6.4, 10.1) | 0.146 |
| Urea, median (IQR), mmol/L | 9.6 (7.6, 13.5) | 9.6 (7.7, 13.1) | 9.6 (7.6, 13.8) | 0.905 |
| Creatinine, median (IQR), umol/L | 117 | 117 | 117 | 0.381 |
| Uric acid, median (IQR), umol/L | 303.5 | 303.5 | 303.5 | 0.270 |
| Triglyceride, median (IQR), mmol/L | 1.8 (1.6, 2.1) | 1.8 (1.6, 2.2) | 1.8 (1.6, 2.1) | 0.814 |
| Cholesterol, median (IQR), mmol/L | 4.5 (4.1, 4.9) | 4.5 (4, 4.9) | 4.5 (4.1, 4.9) | 0.847 |
| Blood glucose, median (IQR), mmol/L | 4.9 (4.5, 5.4) | 4.9 (4.6, 5.5) | 4.9 (4.5, 5.4) | 0.675 |
| Albumin infusion: | 0.982 | |||
| No | 261 (30.2) | 131 (30.4) | 130 (30.1) | |
| Yes | 602 (69.8) | 300 (69.6) | 302 (69.9) | |
| RBC infusion: | 0.805 | |||
| No | 361 (41.8) | 178 (41.3) | 183 (42.4) | |
| Yes | 502 (58.2) | 253 (58.7) | 249 (57.6) |
Figure 2Selection of risk factors of infectious diseases using LASSO regression algorithm. A vertical line was plotted at the given lambda, selected by 10-fold cross-validation with minimum classification error and minimum classification error plus one standard error. For the optimal lambda that gives minimum classification error, 8 features with a non-0 coefficient were selected. (A) LASSO coefficient profiles of the candidate variables. (B) The binomial deviance with 95% CI (y-axis) was plotted against log (lambda) (bottom x-axis), when the number of included variables were changed (upper x-axis). (C) The AUCs with 95% CI (y-axis) were plotted against log (lambda) (bottom x-axis), when the number of included variables were changed (upper x-axis). LASSO, the Least Absolute Shrinkage and Selection Operator; CI, confidence interval; AUC, areas under the curve.
Parameters of ROC curves for prediction of infectious diseases in training set and testing set.
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|
| Training set | 0.50 | 0.78 | 0.76 | 0.80 | 0.76 | 0.81 | 3.85 | 0.29 | 0.76 |
| Testing set | 0.50 | 0.77 | 0.80 | 0.74 | 0.75 | 0.79 | 3.11 | 0.27 | 0.77 |
ACC, Overall accuracy of classification; SENS, Sensitivity; SPEC, Specificity; PPV, Positive predictive value; NPV, Positive predictive value; pDLR, Positive diagnostic likelihood ratio; nDLR, Negative diagnostic likelihood ratio; FSCR, F-score.
Figure 3Performance of the logistic regression algorithm in infectious disease prediction. (A) ROC curves of the training set. (B) ROC curves of the testing set. (C) GiViTI calibration curves of the training set. (D) GiViTI calibration curves of the testing set. ROC, receiver operating characteristic.
Figure 4A nomogram to predict infectious diseases was developed using the predictors selected using LASSO. *P < 0.05, **P < 0.01, ***P < 0.001. LASSO, Least Absolute Shrinkage and Selection Operator.
Figure 5Results of DCA. DCA was performed to compare the nomogram-based decision with default strategies, which assume that all or no observations received interventions. (A) Net benefit against threshold probability in the training set. (B) Net benefit against threshold probability in the testing set. (C) Net reduction in interventions per 100 patients against threshold probability in the training set. (D) Net reduction in interventions per 100 patients against threshold probability in the testing set. DCA, decision curve analysis.